By Dipesh Uprety Dr. Siddhartha Devarakonda, a director of Thoracic Medical Oncology at the Swedish Cancer Institute, presented on…
Pathology's Role in Diagnosing Disparities By: Dr. Srinivas Tantravahi At the Summit On Cancer Disparities conference, Dr. Kamran Mirza, Clinical…
At The Summit on Cancer Health Disparities 2024, in the session titled “Best Practices in Serving LGBTQ+ Communities,” Nakita Venus…
A Discussion on Inclusive Research and Community Engagement Author: Bowen He, MD At The Summit on Cancer Health Disparities 2024,…
By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On April 5, 2024, the Food and Drug Administration granted accelerated approval forfam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi…
By: Dr. Arya Mariam Roy Roswell Park Comprehensive Cancer Center What are immune checkpoint inhibitors? Immune checkpoint inhibitors are a…
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On March 1, 2024, the U.S. Food and Drug Administration approved amivantamab- vmjw (Rybrevant,…
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The FDA gave its approval for the use of osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP)…
By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On February 16, 2024, the U.S. Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi).…
By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On February 15, 2024, the U.S. Food and Drug Administration granted regular approval to tepotinib (Tepmetko)…